LynnElizabethConnollyMD

Infectious Disease • South San Francisco, CA

Physician

Join to view full profile

Dr. Connolly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Connolly's full profile

Already have an account?

Office
1Tower Place
#300
South San Francisco, CA 94080

Education & Training

University of WashingtonFellowship, Infectious Disease, 2003 - 2005
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2001 - 2003
University of California San Francisco School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2002 - 2026
American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

5 citations
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EV...
Michael G Ison, Debra F Weinstein, Marta Dobryanska, Anna Holmes, Anne-Marie Phelan
Open Forum Infectious Diseases. 2023-07-01
4 citations
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3...
Michael G Ison, Myra Popejoy, Nikolay Evgeniev, Maria Tzekova, Kathryn Mahoney
Open Forum Infectious Diseases. 2023-06-01
10 citations
ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae.
Michael R. Jacobs, Caryn E. Good, Andrea M. Hujer, Ayman M. Abdelhamed, Daniel D. Rhoads
Antimicrobial Agents and Chemotherapy. 2020-04-21

Press Mentions

Adagio Therapeutics Launches with $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and ProphylaxisJuly 16th, 2020

Grant Support

Biofilm Formation In Mycobacterial Persistence And Drug Tolerance In VivoNational Institute Of Allergy And Infectious Diseases2008–2010
Biofilm Formation In Mycobacterial Persistence And Drug Tolerance In VivoNational Institute Of Allergy And Infectious Diseases2008